Cargando…

Renoprotection by long‐term low‐dose tolvaptan in patients with heart failure and hyponatremia

AIMS: In previous randomized controlled trials, the use of tolvaptan (TLV) at a fixed dose of 30 mg/day for 1 year did not provide renal benefits in patients with heart failure (HF). This retrospective, cohort study examined the renoprotective effects of long‐term, flexible‐dose, and lower‐dose TLV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oka, Tatsufumi, Hamano, Takayuki, Ohtani, Tomohito, Doi, Yohei, Shimada, Karin, Matsumoto, Ayumi, Yamaguchi, Satoshi, Hashimoto, Nobuhiro, Senda, Masamitsu, Sakaguchi, Yusuke, Matsui, Isao, Nakamoto, Kei, Sera, Fusako, Hikoso, Shungo, Sakata, Yasushi, Isaka, Yoshitaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712924/ https://www.ncbi.nlm.nih.gov/pubmed/34554640 http://dx.doi.org/10.1002/ehf2.13507

Ejemplares similares

Variability in estimated glomerular filtration rate and patients' outcomes in a real‐world heart failure population
por: Oka, Tatsufumi, et al.
Publicado: (2021)

Red cell distribution width and renal outcome in patients with non-dialysis-dependent chronic kidney disease
por: Yonemoto, Sayoko, et al.
Publicado: (2018)

Simple Electrocardiographic Score Can Predict Left Ventricular Reverse Remodeling in Patients With Non-Ischemic Cardiomyopathy
por: Konishi, Shozo, et al.
Publicado: (2019)

Phospholamban p.Arg14del Cardiomyopathy: A Japanese Case Series
por: Tabata, Tomoka, et al.
Publicado: (2021)

Alpha-Klotho is a novel predictor of treatment responsiveness in patients with heart failure
por: Taneike, Manabu, et al.
Publicado: (2021)

A Case of Lymphocytic Myocarditis with Eosinophilic Degranulation Successfully Treated with Steroid Therapy
por: Inoue, Tomoko, et al.
Publicado: (2020)

Polycythemia Vera Associated with Pulmonary Hypertension and Diffuse Large B-Cell Lymphoma: A Case Report
por: Kameda, Satoshi, et al.
Publicado: (2021)

Tolvaptan, hyponatremia, and heart failure
por: Zmily, Hammam D, et al.
Publicado: (2011)

Hidden Hypocalcemia as a Risk Factor for Cardiovascular Events and All-Cause Mortality among Patients Undergoing Incident Hemodialysis
por: Yamaguchi, Satoshi, et al.
Publicado: (2020)

Tolvaptan and its potential in the treatment of hyponatremia
por: Dixon, Megan B, et al.
Publicado: (2008)

Low-grade proteinuria and atherosclerotic cardiovascular disease: A transition study of patients with diabetic kidney disease
por: Yamaguchi, Satoshi, et al.
Publicado: (2022)

Renoprotective effect of tolvaptan in patients with new‐onset acute heart failure
por: Kin, Hiromi, et al.
Publicado: (2020)

First Report of Electromagnetic Interference Between Percutaneous Ventricular Assist Device and Implantable Cardioverter-Defibrillator
por: Takahari, Kosuke, et al.
Publicado: (2023)

Temporal Change in Renoprotective Effect of Tolvaptan on Patients with Heart Failure: AURORA Study
por: Nishino, Masami, et al.
Publicado: (2022)

Pneumopericardium After the Removal of a Pericardiocentesis Drain
por: Tanabe, Junya, et al.
Publicado: (2023)

Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients
por: Nodari, Savina, et al.
Publicado: (2010)

Tolvaptan in the Treatment of Acute Hyponatremia Associated with Acute Kidney Injury
por: Gopinath, Shilpa, et al.
Publicado: (2013)

Tolvaptan for hyponatremia with preserved sodium pool in critically ill patients
por: Umbrello, Michele, et al.
Publicado: (2016)

Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia
por: Wang, Shuzhen, et al.
Publicado: (2018)

Management of hyponatremia associated with acute porphyria—proposal for the use of tolvaptan
por: Solares, Isabel, et al.
Publicado: (2020)

Severe Osteomalacia with Dent Disease Caused by a Novel Intronic Mutation of the CLCN5 gene
por: Matsumoto, Ayumi, et al.
Publicado: (2018)

End-stage Hypertrophic Cardiomyopathy with Advanced Heart Failure in Patients Carrying MYH7 R453 Variants: A Case Series
por: Naito, Susumu, et al.
Publicado: (2023)

Edematous Hyponatremia Treated with Tolvaptan in a Patient with Amyotrophic Lateral Sclerosis
por: Kim, Gheun-Ho
Publicado: (2017)

Renoprotective Benefit of Tolvaptan in Acute Decompensated Heart Failure Patients With Loop Diuretic-Resistant Status
por: Yamamoto, Tomohiko, et al.
Publicado: (2019)

Japan Heart Failure Model　― Derivation and Accuracy of Survival Prediction in Japanese Heart Failure Patients ―
por: Miyagawa, Shigeru, et al.
Publicado: (2018)

Rapidly Progressive Heart Failure in a Female Carrier of Becker Muscular Dystrophy with No Skeletal Muscle Symptoms
por: Komoriyama, Hirokazu, et al.
Publicado: (2019)

Unpredictable Nature of Tolvaptan in Treatment of Hypervolemic Hyponatremia: Case Review on Role of Vaptans
por: Malhotra, Ishan, et al.
Publicado: (2014)

Effect of tolvaptan on hyponatremia in a dog with syndrome of inappropriate secretion of antidiuretic hormone
por: YAMAMOTO, Hiroka, et al.
Publicado: (2023)

Mineralocorticoid Receptor Antagonist Use and Hard Renal Outcomes in Real-World Patients With Chronic Kidney Disease
por: Oka, Tatsufumi, et al.
Publicado: (2022)

Time-updated anion gap and cardiovascular events in advanced chronic kidney disease: a cohort study
por: Asahina, Yuta, et al.
Publicado: (2021)

Diagnosing metabolic acidosis in chronic kidney disease: importance of blood pH and serum anion gap
por: Kaimori, Jun-Ya, et al.
Publicado: (2022)

SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan
por: De las Peñas, Ramón, et al.
Publicado: (2015)

Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone
por: Han, Sang Woong, et al.
Publicado: (2018)

Using Tolvaptan to Treat Hyponatremia: Results from a Post-authorization Pharmacovigilance Study
por: Estilo, Alvin, et al.
Publicado: (2021)

Successful treatment of severe combined post- and pre-capillary pulmonary hypertension in a patient with idiopathic restrictive cardiomyopathy
por: Ishihara, Satomi, et al.
Publicado: (2018)

Low-Dose Tolvaptan for the Treatment of Dilutional Hyponatremia in Cirrhosis: A Case Report and Literature Review
por: Shen, Guo, et al.
Publicado: (2014)

Role of tolvaptan in the management of hyponatremia in patients with lung and other cancers: current data and future perspectives
por: Thajudeen, Bijin, et al.
Publicado: (2016)

Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia
por: Hayashi, Manabu, et al.
Publicado: (2018)

Tolvaptan Versus Fluid Restriction in the Treatment of Hyponatremia Resulting from SIADH Following Pituitary Surgery
por: Kleindienst, Andrea, et al.
Publicado: (2020)

What Are Your Expectations for Risk Prediction Tools?
por: Sotomi, Yohei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9kpfn0fuikj975a1b3pja6t30r